PubMed Health⌕ Search

PubMed · 10763532

[SIDS and polygraphy].

Abstract

The description of an association between central apneas and the sudden infant death syndrome (SIDS) by Steinschneider et al. in 1972 was followed by a sharp rise of polygraphic studies. The hope to use these as a screening method for an increased risk of SIDS could subsequently not be confirmed by prospective studies. Pathological alterations, such as obstructive apneas and hypoxemias, however, seem to have prognostical relevance. They thus represent a focus of current research even though being unable as well to reliably predict a predisposition to SIDS for an individual subject. Instead of being used as a diagnostic tool for SIDS, polygraphic studies have nowadays acquired an accepted role in the investigation of certain physical symptoms and signs such as unexplained 'apparent life threatening events' (ALTE) or cyanotic attacks. Basic technical requirements for a polygraphic laboratory include facilities to record thoracic/abdominal respiration, nasal air flow, ECG/heart rate, oxygen saturation, and to classify different stages of sleep. Registration of additional parameters (EEG, breath sounds, video etc.) is optional, but may prove helpful to arrive at an appropriate diagnosis. Recently, Austrian and German centres have been trying in cooperation to standardize performance conditions and evaluation criteria for polygraphic measurements in pediatric patients under the guidance of the German Association for Sleep Medicine, Pediatric Workgroup. Their aim is to establish common guidelines for the diagnosis and treatment of sleep and arousal disorders in infancy and childhood.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Kerbl. 2000-03-10. [SIDS and polygraphy].. https://pubmed.ncbi.nlm.nih.gov/10763532/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Heart rate changes in response to mild mechanical irritation of the high cervical spinal cord region in infants.

Alterations in the heart rate were monitored before, during and after the application of a unilateral mechanical impulse to the high cervical spinal cord region which was administered strictly in connection with the so called manual therapy (diagnosis= KISS). The investigation is based on a survey of 695 infants between the ages of 1 and 12 months. A notable change in the heart rate was evident in 47.2% of all examined infants (n= 695). In 40.1% of these infants, the change in heart rate was characterized by heart rate decrease of 15-83% compared to control conditions. Infants in their first 3 months of life responded more often with a severe bradycardia (50-83% decrease), older infants (7-12 months) more often with a mild bradycardia (15-49.9% decrease). This comparison revealed a significantly increased occurrence of severe bradycardia in the younger age group compared to the group of children >3 months (significance 0.0017). In 12.1% (n= 84) of the infants, the bradycardia was accompanied by an apnea. We discuss the hypothesis that mechanical irritation of the high-cervical region serves as a trigger that may be involved in sudden infant death (SID).

Apnea↗

Medical devices; apnea monitor; special controls. Final rule.

The Food and Drug Administration (FDA) is issuing a final rule to create a separate classification for the apnea monitor. The device currently is included in the generic type of device called breathing frequency monitors. The apnea monitor will remain in class II, but will be subject to a special control. The special control is an FDA guidance document that identifies minimum performance, testing, and labeling recommendations for the device. Following the effective date of this final classification rule, any firm submitting a 510(k) premarket notification for a "new" apnea monitor will need to address the issues covered in the special control guidance. However, the firm need only show that its device meets the recommendations of the guidance or in some other way provides equivalent assurances of safety and effectiveness. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document that will serve as the special control. FDA is taking these actions because it believes that they are necessary to provide reasonable assurance of the safety and effectiveness of the apnea monitor.

Apnea↗